What is the appropriate outpatient management for a healthy newborn whose mother has congenital adrenal hyperplasia?

Outpatient Management for Healthy Newborn of Mother with CAH

A healthy newborn whose mother has congenital adrenal hyperplasia does not require treatment—the newborn should undergo diagnostic testing to determine their own CAH status, and treatment is only initiated if the infant is affected.

Key Principle: Maternal CAH Does Not Equal Neonatal CAH

The critical distinction here is that CAH is an autosomal recessive disorder—having an affected mother does not automatically mean the newborn has CAH 1. The newborn's risk depends on the father's carrier status:

• If father is unaffected and not a carrier: newborn will be an obligate carrier (heterozygote) but unaffected and asymptomatic
• If father is a carrier: 50% chance newborn is affected
• If father has CAH (rare): 100% chance newborn is affected

Diagnostic Approach for the At-Risk Newborn

1. Newborn Screening

• If available in your region, newborn screening will measure 17-hydroxyprogesterone (17-OHP) 1, 2
• This identifies most cases of classic CAH before symptoms develop
• Screening reduces adrenal crises, prevents incorrect sex assignments, and lowers mortality 2

2. Confirmatory Testing if Screening Positive or Clinical Suspicion

Measure baseline 17-OHP 1:

• >300 nmol/L (>10,000 ng/dL): Likely classic CAH → proceed to treatment
• 6-300 nmol/L (200-10,000 ng/dL): Likely nonclassic CAH or need further testing
• <6 nmol/L (<200 ng/dL): Likely unaffected or heterozygote carrier

If equivocal, perform ACTH stimulation test 1:

• Post-stimulation 17-OHP >300 nmol/L (>10,000 ng/dL) = Classic CAH
• 31-300 nmol/L (1,000-10,000 ng/dL) = Likely nonclassic CAH
• <50 nmol/L (<1,666 ng/dL) = Unaffected or heterozygote

3. Additional Testing for Affected Infants

• Plasma renin activity (PRA) and aldosterone to differentiate salt-wasting from simple virilizing forms 1
• Electrolytes to assess for hyponatremia/hyperkalemia
• Genotyping only if biochemical results are equivocal or for genetic counseling 1

Treatment ONLY If Newborn is Diagnosed with CAH

For Classic CAH (Salt-Wasting or Simple Virilizing):

Glucocorticoid Replacement 1:

• Hydrocortisone tablets: 10-15 mg/m²/day divided into 3 doses
• Avoid oral suspensions and long-acting glucocorticoids (prednisolone, dexamethasone) in growing children due to growth suppression 1
• May temporarily exceed recommended doses initially if markedly elevated androgens, but rapidly reduce once target levels achieved 1

Mineralocorticoid Replacement 1:

• Fludrocortisone: 0.05-0.2 mg/day divided 1-2 times daily
• Sodium chloride supplements: 1-2 g/day (17-34 mEq/day) divided in several feedings
• All classic CAH patients require mineralocorticoid and sodium supplementation in newborn period and early infancy 1

Stress Dosing Education 1:

• Increase glucocorticoid doses for: febrile illness >38.5°C, gastroenteritis with dehydration, surgery with general anesthesia, major trauma
• Do NOT increase for: mental/emotional stress, minor illness, or before physical exercise
• Provide emergency injectable hydrocortisone for home use 3

Monitoring Strategy 1:

• Frequent reassessment needed in infancy to balance androgen suppression vs. glucocorticoid excess
• Monitor for signs of glucocorticoid excess (growth suppression, hypertension, Cushing's syndrome)
• Monitor for inadequate androgen suppression (accelerated bone age, virilization)
• Attempting to completely normalize 17-OHP typically results in overtreatment 1

Critical Pitfalls to Avoid

1. Do not treat a healthy newborn prophylactically just because the mother has CAH—confirm diagnosis first
2. Do not use long-acting glucocorticoids (prednisone, dexamethasone) in infants/children—these cause significant growth suppression 1
3. Do not forget mineralocorticoid replacement—even simple virilizers may benefit, and all salt-wasters require it 1
4. Do not over-suppress androgens—attempting to normalize 17-OHP leads to iatrogenic Cushing's syndrome and growth impairment 1
5. Heterozygote carriers require no treatment—they have slightly elevated post-ACTH 17-OHP but are clinically normal 1

If Newborn is Unaffected

No treatment or ongoing monitoring is required. The child is either a heterozygote carrier (most likely) or completely unaffected, neither of which requires intervention. Genetic counseling may be offered to the family for future reproductive planning 1.